Literature DB >> 19589380

Vascular endothelial growth factor (VEGF) affects processing of amyloid precursor protein and beta-amyloidogenesis in brain slice cultures derived from transgenic Tg2576 mouse brain.

Susanne Bürger1, Monika Noack, Ludmil P Kirazov, Evgeni P Kirazov, Cyrill L Naydenov, Elena Kouznetsova, Yousef Yafai, Reinhard Schliebs.   

Abstract

The up-regulation of the angiogenic vascular endothelial growth factor (VEGF) in brains of Alzheimer patients in close relationship to beta-amyloid (Abeta) plaques, suggests a link of VEGF action and processing of the amyloid precursor protein (APP). To reveal whether VEGF may affect APP processing, brain slices derived from 17-month-old transgenic Tg2576 mice were exposed with 1ng/ml VEGF for 6, 24, and 72h, followed by assessing cytosolic and membrane-bound APP expression, level of both soluble and fibrillar Abeta-peptides, as well as activities of alpha- and beta-secretases in brain slice tissue preparations. Treatment of brain slices with VEGF did not significantly affect the expression level of APP, regardless of the exposure time studied. In contrast, VEGF exposure of brain slices for 6h reduced the formation of soluble, SDS extractable Abeta(1-40) and Abeta(1-42) as compared to brain slice cultures incubated in the absence of any drug, while the fibrillar Abeta peptides did not change significantly. This effect was less pronounced 24h after VEGF exposure, but was no longer detectable when brain slices were exposed by VEGF for 72h, which indicates an adaptive response to chronic VEGF exposure. The VEGF-mediated reduction in Abeta formation was accompanied by a transient decrease in beta-secretase activity peaking 6h after VEGF exposure. To reveal whether the VEGF-induced changes in soluble Abeta-level may be due to actions of VEGF on Abeta fibrillogenesis, the fibrillar status of Abeta was examined using the thioflavin-T binding assay. Incubation of Abeta preparations obtained from Tg2576 mouse brain cortex, in the presence of VEGF slightly decreased the fibrillar content with increasing incubation time up to 72h. The data demonstrate that VEGF may affect APP processing, at least in vitro, suggesting a role of VEGF in the pathogenesis of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19589380     DOI: 10.1016/j.ijdevneu.2009.06.011

Source DB:  PubMed          Journal:  Int J Dev Neurosci        ISSN: 0736-5748            Impact factor:   2.457


  16 in total

1.  Impaired orthotopic glioma growth and vascularization in transgenic mouse models of Alzheimer's disease.

Authors:  Daniel Paris; Nowel Ganey; Magdalena Banasiak; Vincent Laporte; Nikunj Patel; Myles Mullan; Susan F Murphy; Gi-Taek Yee; Corbin Bachmeier; Christopher Ganey; David Beaulieu-Abdelahad; Venkatarajan S Mathura; Steven Brem; Michael Mullan
Journal:  J Neurosci       Date:  2010-08-25       Impact factor: 6.167

2.  Multiple neurotrophic effects of VEGF on cultured neurons.

Authors:  Alma Sanchez; Suchin Wadhwani; Paula Grammas
Journal:  Neuropeptides       Date:  2010-04-28       Impact factor: 3.286

3.  Neural stem cells isolated from amyloid precursor protein-mutated mice for drug discovery.

Authors:  Vito Antonio Baldassarro; Giulia Lizzo; Michela Paradisi; Mercedes Fernández; Luciana Giardino; Laura Calzà
Journal:  World J Stem Cells       Date:  2013-10-26       Impact factor: 5.326

Review 4.  All roads lead to Rome - a review of the potential mechanisms by which exerkines exhibit neuroprotective effects in Alzheimer's disease.

Authors:  Yi-Yao Liang; Li-Dan Zhang; Xi Luo; Li-Li Wu; Zhao-Wei Chen; Guang-Hao Wei; Kai-Qing Zhang; Ze-An Du; Ren-Zhi Li; Kwok-Fai So; Ang Li
Journal:  Neural Regen Res       Date:  2022-06       Impact factor: 5.135

5.  Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer's disease.

Authors:  Liang-Hao Guo; Panagiotis Alexopoulos; Robert Perneczky
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-04-17       Impact factor: 5.270

6.  Exercise training ameliorates cognitive dysfunction in amyloid beta-injected rat model: possible mechanisms of Angiostatin/VEGF signaling.

Authors:  Aliasghar Zarezadehmehrizi; Junyoung Hong; Jonghae Lee; Hamid Rajabi; Reza Gharakhanlu; Naser Naghdi; Mohammad Azimi; Yoonjung Park
Journal:  Metab Brain Dis       Date:  2021-05-18       Impact factor: 3.584

7.  Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis.

Authors:  Rebecca Craig-Schapiro; Max Kuhn; Chengjie Xiong; Eve H Pickering; Jingxia Liu; Thomas P Misko; Richard J Perrin; Kelly R Bales; Holly Soares; Anne M Fagan; David M Holtzman
Journal:  PLoS One       Date:  2011-04-19       Impact factor: 3.240

8.  Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease.

Authors:  Kaan E Biron; Dara L Dickstein; Rayshad Gopaul; Wilfred A Jefferies
Journal:  PLoS One       Date:  2011-08-31       Impact factor: 3.240

9.  Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders.

Authors:  Breno Satler Diniz; Rodrigo Machado-Vieira; Orestes Vicente Forlenza
Journal:  Neuropsychiatr Dis Treat       Date:  2013-04-12       Impact factor: 2.570

Review 10.  The Cerebrovascular Basement Membrane: Role in the Clearance of β-amyloid and Cerebral Amyloid Angiopathy.

Authors:  Alan W J Morris; Roxana O Carare; Stefanie Schreiber; Cheryl A Hawkes
Journal:  Front Aging Neurosci       Date:  2014-09-19       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.